Innovative stem cell technologies have potential to treat Alzheimer’s disease.
search doctoral dissertations texting and driving paper difference between cialis and cialis professional see steps for writers sentences and paragraphs to the essay https://chanelmovingforward.com/stories/write-cheap-critical-analysis-essay-on-shakespeare/51/ scientific literature review example cover letter and resume expository writers service usa sample dissertation proposals free professional dissertation writers service for school go to link follow see url https://www.guidelines.org/blog/essay-steps/93/ viagra on ebay follow http://www.bhcarroll.edu/homework/creative-writing-ks2-bbc/29/ https://jesuswired.com/writing/buy-homework-online/12/ professional dissertation hypothesis ghostwriting sites gb professional essay writers in toronto write sheet music online metformin gastroparesis write outline research paper beowulf essay questions bressay lullaby sheet music custom college school papers corporate social responsibility assignment thesis statement on death camps see go to site Today, there is no cure for Alzheimer’s disease and dementia. In 2015, dementia affected more than 46.8 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 74.7 million in 2030 and to reach 131.5 million in 2050. Stemedica International is the only company to leverage three patented, stem cell technologies (itMSCs, itNSCs and related growth factors) for therapies that may be able to address the global, unmet need for treatments of degenerative conditions, including Alzheimer’s disease and vascular dementia. Stemedica International is also exploring opportunities to prevent the condition, based on promising pre-clinical data.
Stemedica International is using cGMP allogeneic stem cells derived from healthy adult volunteers in clinical trials. Manufactured in a licensed facility under cGMP conditions, the company has successfully completed the safety phase of a clinical trial.